Literature DB >> 15551052

In vitro assessment of a new ABO immunosorbent with synthetic carbohydrates attached to sepharose.

Lennart Rydberg1, Anders Bengtsson, Ola Samuelsson, Kurt Nilsson, Michael E Breimer.   

Abstract

Transplantation across the ABO barrier is sometimes done in cases of emergency, such as acute liver failure, but is also carried out in elective cases, e.g. kidneys from living donors. Reducing the recipient anti-A/B antibody titres is often necessary in ABO-incompatible kidney transplantation. This is usually done by the use of techniques such as plasmapheresis and protein A- or sepharose-linked anti-human Ig immunoadsorption. A new ABO immunosorbent with synthetic A- or B-trisaccharide carbohydrate epitopes linked to a sepharose matrix has been tested. Columns made of this material have been tested in vitro with plasma from A- and B-individuals, assessed for antibody reduction capacity, flow characteristics, biocompatibility, and unspecific protein adsorption. The columns have a high capacity for ABO antibody removal, reducing titres by three to seven steps in one passage. We noted a high biocompatibility, with no unspecific protein adsorption, no activation of coagulation factors, and a low activation of complement, no immune complex formation and no cytotoxicity towards cultured mammalian L929 cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15551052     DOI: 10.1007/s00147-004-0775-7

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  7 in total

1.  Synthetic blood group antigens for anti-A removal device and their interaction with monoclonal anti-A IgM.

Authors:  Jennifer C Solovan; Heung-Il Oh; Azadeh Alikhani; Shalini Gautam; Katherine Vlasova; Elena Y Korchagina; Nicolai V Bovin; William J Federspiel
Journal:  Transpl Immunol       Date:  2006-09-01       Impact factor: 1.708

Review 2.  Recent findings in ABO-incompatible kidney transplantation: classification and therapeutic strategy for acute antibody-mediated rejection due to ABO-blood-group-related antigens during the critical period preceding the establishment of accommodation.

Authors:  Kota Takahashi
Journal:  Clin Exp Nephrol       Date:  2007-06-28       Impact factor: 2.801

3.  High molecular weight blood group A trisaccharide-polyacrylamide glycoconjugates as synthetic blood group A antigens for anti-A antibody removal devices.

Authors:  Azadeh Alikhani; Elena Y Korchagina; Alexander A Chinarev; Nicolai V Bovin; William J Federspiel
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2009-11       Impact factor: 3.368

4.  Selective Capture of Anti-N-glucosylated NTHi Adhesin Peptide Antibodies by a Multivalent Dextran Conjugate.

Authors:  Antonio Mazzoleni; Feliciana Real-Fernandez; Francesca Nuti; Roberta Lanzillo; Vincenzo Brescia Morra; Paolo Dambruoso; Monica Bertoldo; Paolo Rovero; Jean-Maurice Mallet; Anna Maria Papini
Journal:  Chembiochem       Date:  2021-12-06       Impact factor: 3.461

Review 5.  Therapeutic apheresis in kidney transplantation: An updated review.

Authors:  Maurizio Salvadori; Aris Tsalouchos
Journal:  World J Transplant       Date:  2019-10-28

6.  Capsid-specific removal of circulating antibodies to adeno-associated virus vectors.

Authors:  Berangere Bertin; Philippe Veron; Christian Leborgne; Otto Merten; Federico Mingozzi; Jack-Yves Deschamps; Sophie Moullec; Yves Fromes; Fanny Collaud; Sylvie Boutin; Virginie Latournerie; Laetitia van Wittenberghe; Benoit Delache; Roger Le Grand; Nathalie Dereuddre-Bosquet; Olivier Benveniste; Philippe Moullier; Carole Masurier
Journal:  Sci Rep       Date:  2020-01-21       Impact factor: 4.379

7.  The First North American Experience Using Glycosorb Immunoadsorption Columns for Blood Group-Incompatible Kidney Transplantation.

Authors:  Katerina Pavenski; Megan Bucholz; Patti Lou Cheatley; Elizabeth Krok; Monique Anderson; Gv Ramesh Prasad; Mohammed Azfar Qureshi; Galo Meliton; Jeffrey Zaltzman
Journal:  Can J Kidney Health Dis       Date:  2020-10-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.